Abstract
New classes of antidiabetics offer not only efficient but also safe therapy of diabetes. The beneficial influence on different markers of renal impairment was determined in clinical trials with these medicinal products.
Glukagon-like peptide 1 (GLP-1) receptor agonists show prominent positive effect on the risk of development and progression of albuminuria. Gliflozins (SGLT2 inhibitors) slow down the progression of estimated glomerular filtration decrease.
The body of evidence suggests that these are class-specific effects. In high-risk population, these drugs also decrease the risk of terminal renal failure.